These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31622064)

  • 21. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
    Link H; Kerkmann M; Holtmann L; Ortner P;
    Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
    Kuderer NM; Dale DC; Crawford J; Lyman GH
    J Clin Oncol; 2007 Jul; 25(21):3158-67. PubMed ID: 17634496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of granulocyte colony-stimulating factor prophylaxis for febrile neutropenia in breast cancer in the United Kingdom.
    Whyte S; Cooper KL; Stevenson MD; Madan J; Akehurst R
    Value Health; 2011 Jun; 14(4):465-74. PubMed ID: 21669371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.
    Younis T; Rayson D; Jovanovic S; Skedgel C
    Breast Cancer Res Treat; 2016 Oct; 159(3):425-32. PubMed ID: 27572552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessment.
    Weycker D; Bensink M; Lonshteyn A; Doroff R; Chandler D
    Curr Med Res Opin; 2019 Jun; 35(6):1073-1080. PubMed ID: 30550346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
    Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Annual patient and caregiver burden of oncology clinic visits for granulocyte-colony stimulating factor therapy in the US.
    Stephens JM; Li X; Reiner M; Tzivelekis S
    J Med Econ; 2016; 19(5):537-47. PubMed ID: 26745764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma--a cost-effectiveness analysis.
    Numnum TM; Kimball KJ; Rocconi RP; Kilgore LC; Straughn JM
    Int J Gynecol Cancer; 2007; 17(5):1019-24. PubMed ID: 17386043
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
    Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
    Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
    Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
    J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use and effectiveness of pegfilgrastim prophylaxis in US clinical practice:a retrospective observational study.
    Weycker D; Doroff R; Hanau A; Bowers C; Belani R; Chandler D; Lonshteyn A; Bensink M; Lyman GH
    BMC Cancer; 2019 Aug; 19(1):792. PubMed ID: 31399079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy.
    Chan KK; Siu E; Krahn MD; Imrie K; Alibhai SM
    J Clin Oncol; 2012 Apr; 30(10):1064-71. PubMed ID: 22393098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment : An expert view.
    Gascón P; Awada A; Karihtala P; Lorenzen S; Minichsdorfer C
    Wien Klin Wochenschr; 2024 Jun; 136(11-12):362-368. PubMed ID: 38010512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis.
    Cheung MC; Prica A; Graczyk J; Buckstein R; Chan KK
    Leuk Lymphoma; 2016 Aug; 57(8):1865-75. PubMed ID: 26758765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
    Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Appropriateness of using granulocyte colony-stimulating factor (G-CSF) for primary prophylaxis of febrile neutropenia in solid tumors.
    Laali E; Fazli J; Sadighi S; Mohammadi M; Gholami K; Jahangard-Rafsanjani Z
    J Oncol Pharm Pract; 2020 Mar; 26(2):428-433. PubMed ID: 31615347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
    Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J
    BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.